The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.
Patients with advanced non-small cell lung cancer with an EGFR mutation had a greater risk reduction for disease progression with frontline Rybrevant plus Leclaza compared with Tagrisso alone.
Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda plus endocrine therapy generated a statistically significant increase in pathologic complete response compared to pre-surgical placebo and chemotherapy followed by adjuvant Keytruda and endocrine therapy for patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.
Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.
Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed.
The addition of Keytruda to Xtandi showed no improvements for radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.
Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer.
For the first time, a drug combination (Padcev plus Keytruda) outperformed frontline chemotherapy for patients with locally advanced or metastatic urothelial carcinoma.
The combination of Lumakras and Vectibix led to better progression-free survival compared with standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.
Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival.
Welireg led to improved time to progression and objective response rates compared to Afinitor for patients with advanced clear cell renal cell carcinoma, according to study findings.
Treatment with Retevmo, compared with Cabometyx or Caprelsa, improved progression-free survival and overall response rate in patients with advanced RET-mutant medullary thyroid cancer who were multikinase inhibitor-naïve.
The treatment combination of Rybrevant plus chemotherapy offers better progression-free survival for patients with advanced EGFR exon 20 insertion-positive NSCLC.
Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer.
Patients with ALK-positive, early-stage non-small cell lung cancer obtained significant improvement in disease-free survival.
Treating patients with Tagrisso, a tyrosine kinase inhibitor, plus chemotherapy reduced the progression risk of disease of the central nervous system in patients with EGFR-positive non-small cell lung cancer.
Treatment with neoadjuvant Opdivo, followed by Opdivo after surgery led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.
Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
The phase 3 FLAMES trial showed a benefit of progression-free survival with senaparib compared to placebo in patients with newly diagnosed, advanced ovarian cancer.
Some patients with breast cancer who took Verzenio plus endocrine therapy two years after initial treatment demonstrated improved efficacy.
Patients with previously treated small cell lung cancer who received a 10-mg dose of tarlatamab had improved responses with no new safety signals.
Even with the increase of immunotherapy utilization to treat patients with advanced renal cell carcinoma, more research is needed to determine in which order to administer it as later lines of therapy.
Therapies that target specific characteristics on kidney cancer cells are showing promise in the space, an expert explained.
With new treatments being explored, it’s an exciting time for patients with kidney cancer, an expert explained.
An expert explained what aspects of a patient’s disease cancer care teams use to determine the best treatment options for patients with clear cell renal cell carcinoma.
Patients with BAP1-mutated renal cell carcinoma who were treated with Lynparza obtained responses with favorable side effect profiles.
An expert gives an overview of up-and-coming treatments for patients with kidney cancer.
Long-term follow-up data showed that Lenvima plus Keytruda continued to show benefit in patients with metastatic kidney cancer.
Immunotherapy combinations tended to improve outcomes for patients with metastatic kidney cancer who go on to receive surgery.
